Skip to main content
SpringerLink
Log in

Localisation uro-génitale

  • Chapter
Tumeurs malignes rares

  • 49 Accesses

Résumé

Les tumeurs à petites cellules (ou carcinomes à petites cellules, ou carcinomes endocrines à petites cellules) sont des tumeurs malignes endocrines peu différenciées, dont la localisation primitive est surtout pulmonaire. Les primitifs extrapulmonaires sont toutefois connus de longue date (1) et peuvent être de site urologique, en particulier vésical ou prostatique. La majorité des tumeurs urologiques endocrines sont en fait mixtes, avec un contingent tumoral endocrine et un autre épithélial. Il n’y a pas de consensus sur le pourcentage de composante endocrine qui serait nécessaire pour retenir le diagnostic. De même, il peut y avoir une variabilité au cours du temps de la proportion du contingent endocrine, qui devient progressivement prédominant, notamment au cours de l’évolution d’un cancer de la prostate initialement mixte. Les formes de tumeurs à petites cellules d’emblée pures existent mais sont nettement plus rares. Dans ces cas, il peut être nécessaire de vérifier que la localisation urologique n’est pas une métastase d’un primitif bronchique (2).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. Duguid JB, Kennedy AM (1930) Oat cell tumors of mediastinal glands. J Pathol Bacteriol 33: 93–99

    Article  Google Scholar 

  2. Hodge GB, Carson CC (1985) Oat cell carcinoma of lung masquerading as prostatic carcinoma. Urology 25: 69–70

    Article  PubMed  Google Scholar 

  3. Pearse AG, Takor T (1979) Embryology of the diffuse neuroendocrine system and its relationship to the common peptides. Fed Proc 38: 2288–94

    CAS  PubMed  Google Scholar 

  4. Schron DS, Gibson T, Mendelsohn G (1984) The histogenesis of small cell carcinoma of the prostate. An immunohistochemical study. Cancer 53: 2478–80

    Article  CAS  PubMed  Google Scholar 

  5. Cheng L, Jones TD, Mc Carthy RP, et al. (2005) Molecular genetic evidence for a common clonal origin of urinary bladder small cell carcinoma and coexisting urothelial carcinoma. Am J Pathol 166: 1533–9

    Article  CAS  PubMed  Google Scholar 

  6. Helpap BB, Kollermann J, Ochler U (1999) Neuroendocrine differentiation in prostatic carcinomas: histogenesis, biology, clinical relevance, and future therapeutical perspectives. Urol Int 62: 133–8

    Article  CAS  PubMed  Google Scholar 

  7. Cheng L, Pan CX, Yang XL, et al. (2004) Small cell carcinoma of the urinary bladder: a clinicopathologic analysis of 64 patients. Cancer 101: 957–62

    Article  PubMed  Google Scholar 

  8. Quek ML, Nichols PW, Yamzom J, et al. (2005) Radical cystectomy for primary neuroendocrine tumors of the bladder: the university of southern california experience. J Urol 174: 93–6

    Article  PubMed  Google Scholar 

  9. Choong NW, Ouevedo JF, Kaur JS (2005) Small cell carcinoma of the urinary bladder. The Mayo Clinic experience. Cancer 15: 1172–8

    Article  Google Scholar 

  10. Tigert R, Ravery V, Gheiler EL, et al. (1999) Primary small cell carcinoma of the bladder Prog Urol 9: 256–60

    Google Scholar 

  11. Oesterling JE, Hauzeur CG, Farrow GM (1992) Small cell anaplastic carcinoma of the prostate: a clinical, pathological and immunohistological study of 27 patients. J Urol 147: 804–7

    CAS  PubMed  Google Scholar 

  12. Spieth ME, Lin YG, N’guyen TT (2002) Diagnosing and treating small-cell carcinoma of prostatic origin: Clin Nuc Med 27: 11–7

    Article  Google Scholar 

  13. McCoutcheon IE, Eng DY, Logothetis CJ (1999) Brain metastasis from prostate carcinoma: antemortem recognition and outcome after treatment. Cancer 86: 2301–11

    Article  Google Scholar 

  14. Baird AD, Comford PA, Helliwell T, et al. (2002) Small cell prostate cancer with anti-Hu positive peripheral neuropathy. J Urol 168: 192

    Article  CAS  PubMed  Google Scholar 

  15. Haukaas SA, Halyorsen OJ, Nygaard SJ, et al. (1999) Cushing’s syndrome in prostate cancer. An aggressive course of prostatic malignancy. Urol Int 63: 126–9

    Article  CAS  PubMed  Google Scholar 

  16. Karadeniz-Bilgily MY, Semelka RC, Hyslop WB, et al. (2005) MRI findings of primary small-cell carcinoma of kidney. Magn Reson Imaging 23: 515–7

    Article  Google Scholar 

  17. Ro JY, et al. (1987) Small cell carcinoma of the prostate. Immunohistochemical and electron microscopy studies of 18 cases. Cancer 59: 977–82

    Article  CAS  PubMed  Google Scholar 

  18. Cabrespine A, Guy L, Gachon F, et al. (2006) Circulating chromogranin A and hormone refractory prostate cancer chemotherapy J Urol 175: 1347–52

    Article  CAS  PubMed  Google Scholar 

  19. Birtle AJ, Freeman A, Masters JR, et al. (2005) Tumour markers for managing men who present with metastatic prostate cancer and serum prostate-specific antigen levels of < 10 ng/mL. BJU Int 96: 303–7

    Article  PubMed  Google Scholar 

  20. Kilicarsalan Akkaya B, Mustafa U, Esin O, et al. (2003) Primary small cell carcinoma of the kidney. Urol Oncol 21: 11–3

    PubMed  Google Scholar 

  21. Majhail NS, Elson P, Bukowski RM (2003) Therapy and outcome of small cell carcinoma of the kidney: report of two cases and a systematic review of the literature. Cancer 97: 1436–41

    Article  PubMed  Google Scholar 

  22. Asmis TR, Reaume MN, dahrouge S, et al. (2006) Genitourinary small cell carcinoma: a retrospective review of treatment and survival patterns at The Ottawa Hospital Regional Cancer Center. BJU Int 97: 711–5

    Article  PubMed  Google Scholar 

  23. Kawahara T, nishiyama H, Yamamoto S, et al. (2006) Protocol consisting of cisplatin, etoposide and irinotecan induced complete pathological remission of primary small cell carcinoma of the bladder. Int J Urol 13: 1251–3

    Article  PubMed  Google Scholar 

  24. Bez A, Niewenhuijzen JA, Kerst M, et al. (2005) Small cell carcinoma of bladder: a single-center prospective study of 25 cases treated in analogy to small cell lung cancer. Urology 65: 295–9

    Article  Google Scholar 

  25. Papandreou CN, Daliani DD, Thall PF, et al. (2002) Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J Clin Oncol 15: 3072–80

    Article  Google Scholar 

  26. Siefert-Radke AO, Dinney CF, Abrahams NA, et al. (2004) Evidence supporting preoperative chemotherapy for small cell carcinoma of the bladder: a retrospective review of the M. D. Anderson cancer experience. J Urol 172: 481–4

    Article  Google Scholar 

  27. Amato RJ, Logothetis CJ, Halliman R, et al. (1992) Chemotherapy for small cell carcinoma of prostatic origin. J Urol 147: 935–7

    CAS  PubMed  Google Scholar 

  28. Weinstein MH, Partin AW, Veltri RW, Epstein JI (1996) Neuroendocrine differentiation in prostate cancer: enhanced prediction of progression after radical prostatectomy. Hum Pathol 27: 683–7

    Article  CAS  PubMed  Google Scholar 

  29. Brink I, Schumaker T, Mix M, et al. (2004) Impact of [18F]FDG-PET on the primary staging of small-cell lung cancer. Eur J Nucl Med Mol Imaging. 31: 1614–20

    Article  CAS  PubMed  Google Scholar 

  30. Maulard C, Richaud P, Droz JP, et al. (1995) Phase I-II study of the somatostatin analogue lanreotide in hormone-refractory prostate cancer. Cancer Chemother Pharmacol 36: 259–62

    Article  CAS  PubMed  Google Scholar 

  31. Bernhart P, Ahlman H, Nilsson O, et al. (2003) Evaluation of (111)In labeled somatostatin analogs for targeted therapy of somatostatin receptor positive tumors. Cancer Biother Radiopharm 18: 249–52

    Article  Google Scholar 

  32. Pless M, Waldherr C, Maecke H, et al. (2004) Targeted radiotherapy for small cell lung cancer using 90Yttrium-DOTATOC, an Yttrium-labelled somatostatin analogue: a pilot trial Lung cancer 45: 365–771

    Google Scholar 

  33. Pan CX, Yang XJ, Lopez-Beltran A, et al. (2005) c-kit Expression in small cell carcinoma of the urinary bladder: prognostic and therapeutic implications. Mod Pathol 18: 320–3

    Article  CAS  PubMed  Google Scholar 

  34. Abrams TJ, Lee LB, Murray LJ, et al. (2003) SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2: 471–8

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Département de cancérologie médicale, Institut Claudius-Regaud, 20-24, rue du Pont-Saint-Pierre, 21052, Toulouse Cedex

    C. Théodore

Authors
  1. C. Théodore
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer-Verlag France, Paris

About this chapter

Cite this chapter

Théodore, C. (2010). Localisation uro-génitale. In: Tumeurs malignes rares. Springer, Paris. https://doi.org/10.1007/978-2-287-72070-3_37

Download citation

  • DOI: https://doi.org/10.1007/978-2-287-72070-3_37

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-287-72069-7

  • Online ISBN: 978-2-287-72070-3

Publish with us

Policies and ethics

Search

Navigation